LP-184 by Starlight Therapeutics for Melanoma: Likelihood of Approval

LP-184 is under clinical development by Starlight Therapeutics and currently in Phase I for Melanoma.

BTK Inhibitor Reduces Brain Lesions in Relapsing MS

MILAN — Investigational fenebrutinib reduced brain lesions in relapsing multiple sclerosis (MS) patients and showed evidence of central nervous system (CNS) penetration, data from the

October 20, 2023

New Rule Allows HIV-Positive Organ Transplants

People with HIV who need a kidney or liver transplant will be able to receive an organ from a donor with HIV under a new

November 27, 2024

Optimi Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent – Psychedelic Alpha

VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug

August 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.